CoChat

Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy

Open access
Nakamura, Yoshio, Kitano, Shigehisa, Takahashi, Akira, Tsutsumida, Arata, Namikawa, Kenjiro, Tanese, Keiji, Abe, Takayuki, Funakoshi, Takeru, Yamamoto, Noboru, Amagai, Masayuki, Yamazaki, Naoya · 2016 · Oncotarget
Cited by 164

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

// Yoshio Nakamura 1, 3 , Shigehisa Kitano 2, * , Akira Takahashi 1 , Arata Tsutsumida 1 , Kenjiro Namikawa 1 , Keiji Tanese 3 , Takayuki Abe 4 , Takeru Funakoshi 3 , Noboru Yamamoto 2 , Masayuki Amagai 3 , Naoya Yamazaki 1, * 1 Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan 2 Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan 3 Department of Dermatology, Keio University School of Medicine, Tokyo, Japan 4 Department of Preventive Medicine and Public Health, Biostatistics Unit at Clinical Translational Research Center, Keio University School of Medicine, Tokyo, Japan * These authors have contributed equally to this work Correspondence to: Shigehisa Kitano, email: skitano@ncc.go.jp Keywords: nivolumab, metastatic melanoma, absolute lymphocyte count, absolute neutrophil count, early markers for outcome Received: June 07, 2016 Accepted: September 28, 2016 Published: October 15, 2016 ABSTRACT Background: An anti-programmed cell death protein 1 monoclonal antibody, nivolumab, is one of the most effective drugs for advanced melanoma. Tumor cell-derived or immune cell-derived markers and clinical predictors such as serum lactate dehydrogenase (LDH) and cutaneous adverse events, have already been described as prognostic factors for advanced melanoma treated with nivolumab. We sought to identify further clinical predictors that can be determined in routine clinical practice. Methods: We retrospectively analyzed clinical findings of 98 consecutive patients with unresectable stage III or IV melanoma treated with nivolumab, at the National Cancer Center Hospital or at Keio University Hospital, in Tokyo, Japan, between July 2014 and July 2016. These patients had been administered nivolumab at a dose of 2mg/kg every 3 weeks. Results: As for pretreatment prognostic factors, ECOG performance status (PS) ≥1, maximum tumor diameters of ≥30mm, elevated LDH and elevated C-reactive protein were significantly associated with poor overall survival (OS) (hazard ratio [HR] 0.29 [ P <0.001], HR 0.40 [ p =0.003], HR 0.29 [ P <0.001], HR 0.42 [ P =0.004], respectively) on univariate analysis. Among these factors, PS and LDH were identified as independent variables by multivariate analysis. As for early markers examined during therapy, patients with absolute lymphocyte count (ALC) ≥ 1000/μl (Week3: HR 0.40 [ P =0.004], Week6: HR 0.33 [ P =0.001]) and absolute neutrophil count (ANC) <4000/μl (Week3: HR 0.46 [ P =0.014], Week6: HR 0.51 [ P =0.046]) had significantly better OS. Conclusion: ALC≥1000/μl and ANC<4000/μl during treatment appear to be early markers associated with OS. Nivolumab might have minimal efficacy in patients with a massive tumor burden.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.12677

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 164

Metadata

Authors
Nakamura, Y., Kitano, S., Takahashi, A., Tsutsumida, A., Namikawa, K., Tanese, K., Abe, T., Funakoshi, T., Yamamoto, N., Amagai, M., & Yamazaki, N.
Venue
Oncotarget
Published
2016-10-15
Volume
7
Issue
47
Pages
77404-77415
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2531648809
Cited by
164
References
14
FWCI
12.21
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. https://app.cochat.ai/papers/10.18632/oncotarget.12677
The paper
Nakamura, Y., Kitano, S., Takahashi, A., Tsutsumida, A., Namikawa, K., Tanese, K., Abe, T., Funakoshi, T., Yamamoto, N., Amagai, M., & Yamazaki, N. (2016). Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget. https://doi.org/10.18632/oncotarget.12677

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.